The MHC-I pathway is critical for the efficacy of ICB, and earlier studies have identified enriched protein expression of the MHC-I/APM pathway members in patients with melanoma responding to anti-PD1 therapy (Supplemental Figure 4C and ref. 32), a standard therapy for patients with melanoma (32, 33). Here, ANPEP is linked to melanoma.